Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Levy

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 28, 2012
Versican 3'-untranslated region (3'-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activityLing Fang, William W Du, Xiangling Yang, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 7, 2006
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month resultsGary Levy, Heinz Schmidli, Jeffrey Punch, et al.
Clinical Transplantation|June 28, 2018
Live donor liver transplantation with older donors: Increased long-term graft loss due to HCV recurrenceNicolas Goldaracena, Andrew S Barbas, Antonio Galante, et al.
Journal of Hepatology|July 8, 2019
Donor outcomes in anonymous live liver donationNicolas Goldaracena, Judy Jung, Aloysious D Aravinthan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 14, 2017
Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter studyLong-Bin Jeng, Sung Gyu Lee, Arvinder Singh Soin, et al.
Hepatology (Baltimore, Md.)|December 17, 2008
The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitisItay Shalev, Kit Man Wong, Katharina Foerster, et al.
Transplantation|March 20, 2021
Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled TrialsSung-Gyu Lee, Long-Bin Jeng, Faouzi Saliba, et al.
JAMA|December 25, 2003
Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary studyMona R Loutfy, Lawrence M Blatt, Katharine A Siminovitch, et al.
Antiviral Therapy|May 4, 2005
Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroidsSarah E Ward, Mona R Loutfy, Lawrence M Blatt, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2007
Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritisItay Shalev, Hao Liu, Cheryl Koscik, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 28, 2012
Versican 3'-untranslated region (3'-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activityLing Fang, William W Du, Xiangling Yang, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 7, 2006
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month resultsGary Levy, Heinz Schmidli, Jeffrey Punch, et al.
Clinical Transplantation|June 28, 2018
Live donor liver transplantation with older donors: Increased long-term graft loss due to HCV recurrenceNicolas Goldaracena, Andrew S Barbas, Antonio Galante, et al.
Journal of Hepatology|July 8, 2019
Donor outcomes in anonymous live liver donationNicolas Goldaracena, Judy Jung, Aloysious D Aravinthan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 14, 2017
Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter studyLong-Bin Jeng, Sung Gyu Lee, Arvinder Singh Soin, et al.
Hepatology (Baltimore, Md.)|December 17, 2008
The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitisItay Shalev, Kit Man Wong, Katharina Foerster, et al.
Transplantation|March 20, 2021
Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled TrialsSung-Gyu Lee, Long-Bin Jeng, Faouzi Saliba, et al.
JAMA|December 25, 2003
Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary studyMona R Loutfy, Lawrence M Blatt, Katharine A Siminovitch, et al.
Antiviral Therapy|May 4, 2005
Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroidsSarah E Ward, Mona R Loutfy, Lawrence M Blatt, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2007
Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritisItay Shalev, Hao Liu, Cheryl Koscik, et al.
Pageof 8